Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada
October 15th, 2018
Advicenne (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial for the treatment of distal Renal Tubular Acidosis (dRTA) in Canada from Health Canada’s Office of Clinical Trial…